Cargando…
Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
Autores principales: | Foy, Susan P, Rountree, Ryan B, Cote, Joseph, dela Cruz, Tracy, Gordon, Evan, Trent, Erica, Franzusoff, Alex, Breitmeyer, James B, Mandl, Stefanie J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288427/ http://dx.doi.org/10.1186/2051-1426-2-S3-P124 |
Ejemplares similares
-
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
por: Foy, Susan P., et al.
Publicado: (2016) -
Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
por: Foy, Susan P, et al.
Publicado: (2013) -
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
por: Foy, Susan P., et al.
Publicado: (2016) -
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
por: Mandl, Stefanie J, et al.
Publicado: (2014) -
Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus
por: Cho, Euna, et al.
Publicado: (2018)